Literature DB >> 7130741

Serum levels of 8-methoxypsoralen in two different drug preparations: correlation with photosensitivity and UV-A dose requirements for photochemotherapy.

H Hönigsmann, E Jaschke, V Nitsche, W Brenner, W Rauschmeier, K Wolff.   

Abstract

In a quantitative study we have compared the serum levels, the time course and the photosensitizing capacity of a conventional crystalline 8-methoxypsoralen brand and an investigational liquid formula. Evidence is presented showing that the liquid preparation is superior to the crystalline form: it peaks earlier after ingestion, it produces higher and more constant degree of photosensitization, it is eliminated more rapidly from the blood, and it requires a lower UV-A dose for eliciting photosensitivity reactions aiming at a reduction of the total cumulative UV-A dose required for clearing psoriasis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7130741     DOI: 10.1111/1523-1747.ep12500068

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

1.  Comparison of serum levels and clinical results of PUVA therapy with three different dosage forms of 8-methoxypsoralen.

Authors:  A H Siddiqui; L M Stolk; R H Cormane
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

2.  Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration.

Authors:  Marcella Grundmann-Kollmann; Maurizio Podda; Lutz Bräutigam; Katja Hardt-Weinelt; Ralf J Ludwig; Gerd Geisslinger; Roland Kaufmann; Irmgard Tegeder
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 3.  5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of methoxsalen and other psoralens.

Authors:  F A de Wolff; T V Thomas
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.